Felipe Luz

Felipe Luz


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Surgical Oncology
Verified
Journal Article
Closed access
FLFelipe Luz
Felipe Luz
EMEduarda da Costa Marinho
Eduarda da Costa Marinho
CNCamila Piqui Nascimento
Camila Piqui Nascimento
LMLara de Andrade Marques
Lara de Andrade Marques
MDMateus Bringel Oliveira Duarte
Mateus Bringel Oliveira Duarte
MSMarcelo José Barbosa Silva
Marcelo José Barbosa Silva

14 September 2022 in Surgical Oncology
Verified
Journal Article
Closed access
FLFelipe Luz
Felipe Luz
EMEduarda da Costa Marinho
Eduarda da Costa Marinho
CNCamila Piqui Nascimento
Camila Piqui Nascimento
LMLara de Andrade Marques
Lara de Andrade Marques
PDPatrícia Ferreira Ribeiro Delfino
Patrícia Ferreira Ribeiro Delfino
MSMarcelo José Barbosa Silva
Marcelo José Barbosa Silva

20 January 2022 in ecancermedicalscience
Verified
Journal Article
Open access
FLFelipe Luz
Felipe Luz
EMEduarda da Costa Marinho
Eduarda da Costa Marinho
CNCamila Piqui Nascimento
Camila Piqui Nascimento
LMLara de Andrade Marques
Lara de Andrade Marques
PDPatrícia Ferreira Ribeiro Delfino
Patrícia Ferreira Ribeiro Delfino
RARogério Agenor de Araújo
Rogério Agenor de Araújo
The benefits of trastuzumab in the treatment of HER2+ breast cancer as a function of exposure time Felipe Andrés Cordero da Luz1,2a, Eduarda da Costa Marin

3 March 2022 in ecancermedicalscience
Verified
Journal Article
Open access
FLFelipe Luz
Felipe Luz
EMEduarda da Costa Marinho
Eduarda da Costa Marinho
CNCamila Piqui Nascimento
Camila Piqui Nascimento
LMLara de Andrade Marques
Lara de Andrade Marques
PDPatrícia Ferreira Ribeiro Delfino
Patrícia Ferreira Ribeiro Delfino
MSMarcelo Silva
Marcelo Silva
Prognosis value of lymphovascular invasion in patients with invasive ductal breast carcinoma according to lymph node metastasis status Felipe Andrés Corder

17 July 2023 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
RARogério Agenor de Araújo
Rogério Agenor de Araújo
FLFelipe Luz
Felipe Luz
EMEduarda da Costa Marinho
Eduarda da Costa Marinho
CNCamila Piqui Nascimento
Camila Piqui Nascimento
TMThais Rezende Mendes
Thais Rezende Mendes
MSMarcelo Silva
Marcelo Silva

19 July 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
FLFelipe Luz
Felipe Luz
RARogério A. Araújo
Rogério A. Araújo
MSMarcelo J. B. Silva
Marcelo J. B. Silva
Purpose: Sentinel-lymph-node (SLN) biopsy (SLB) is an efficient and safe axillary surgical approach with decreased morbidity than total axillary lymph node dissection (ALND) in initial patients (T1–T2). Current guidelines strongly suggest avoiding completion of ALND in patients with one or two positive SLNs that will be submitted to whole-breast radiation therapy, but must be done when three SLNs are affected.Methods: We performed a SEER-based study with breast invasive ductal carcinoma patients treated between 2010 and 2015. Optimal cutoffs of positive LNs predictive of survival were obtained with ROC curves and survival as a continuous variable. Bias was reduced through propensity score matching. Cox regression was employed to estimate prognosis. Nomograms were constructed to analyze the predictive value of clinicopathological factors for axillary burden.Results: Of 43,239 initial patients that had one to three analyzed LNs, only 425 had two positive LNs and matched analysis demonstrated no survival difference versus pN2 patients [HR: 0.960 (0.635–1.452), p = 0.846]. The positive-to-analyzed LN proportion demonstrated a strong prognostic factor for a low rate (1 positive to ≤1.5 analyzed) [HR = 1.567 (1.156–2.126), p = 0.004], and analysis derived from the results demonstrated that a “negative LN margin” improves survival. Nomograms shows that tumor size is the main factor of axillary burden.Conclusion: Macrometastasis of two LNs is a poor prognostic factor, similar to pN2, in SLNB (-like) patients; more extensive studies including preconized therapies must be done in order to corroborate or refute the resistance of this prognostic difference in patients with two macrometastatic lymph nodes within few resected.